BNP Paribas Asset Management
XENE icon

BNP Paribas Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

BNP Paribas Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.9M Sell
1,290,731
-51,297
-4% -$2.85M 0.08% 238
2026
Q1 		$78M Buy
1,342,028
+281,807
+27% +$13M 0.09% 229
2025
Q4 		$47.5M Buy
1,060,221
+389,964
+58% +$16.4M 0.05% 317
2025
Q3 		$26.9M Buy
670,257
+9,175
+1% +$323K 0.07% 281
2025
Q2 		$20.7M Sell
661,082
-42,713
-6% -$1.39M 0.05% 343
2025
Q1 		$23.6M Buy
703,795
+40,091
+6% +$1.52M 0.06% 297
2024
Q4 		$26M Buy
663,704
+224,630
+51% +$9.29M 0.06% 286
2024
Q3 		$17.3M Buy
439,074
+17,953
+4% +$724K 0.04% 334
2024
Q2 		$16.4M Buy
421,121
+4,385
+1% +$175K 0.04% 331
2024
Q1 		$17.9M Buy
+416,736
New +$19.2M 0.05% 320

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management's XENE Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 3.8% in Q2 2026, selling an estimated $2.85M and leaving 1,290,731 shares worth $77.9M. The position accounts for 0.08% of the portfolio, ranked #238.

BNP Paribas Asset Management first reported a position in XENE in Q1 2024 and has held it in 10 quarters since. The position peaked at $78M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • BNP Paribas Asset Management held 1,290,731 shares of Xenon Pharmaceuticals worth $77.9M as of Q2 2026.
  • BNP Paribas Asset Management sold 51,297 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.85M.
  • Xenon Pharmaceuticals made up 0.08% of BNP Paribas Asset Management's portfolio in Q2 2026, its #238 holding.
  • BNP Paribas Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • BNP Paribas Asset Management's Xenon Pharmaceuticals position peaked at $78M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.